Learn how the 12-year biologic exclusivity rule under the BPCIA delays biosimilar entry, impacting drug prices and patient access in the US compared to global markets.
Sep, 6 2024
Dec, 1 2025
Jul, 8 2026
Jan, 9 2026
Nov, 25 2025